BRD9876 |
| Catalog No.GC48901 |
BRD9876은 강화된 미세소관(MT) 결합이 있는 상태에서 키네신-5(Eg5)를 고정시켜 MT의 번들링 및 안정화를 유도하는 \BRD9876 is the "rigor" inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs.en_ko_2021q1.mdBRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket.en_ko_2021q1.mdBRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells.en_ko_2021q1.mdBRD9876 has the potential for multiple myeloma (MM) research.en_ko_2021q1.md
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 32703-82-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BRD9876 is an inhibitor of the kinesin spindle protein Eg5.1 It arrests Eg5-mediated microtubule gliding, as well as inhibits Eg5 ATPase activity in the presence of microtubules, in cell-free assays. BRD9876 is cytotoxic to MM.1S stroma-independent multiple myeloma cells (IC50 = 2.2 µM). It induces cell cycle arrest at the G2/M phase in MM.1S cells when used at a concentration of 10 µM.
1.Chattopadhyay, S., Stewart, A.L., Mukherjee, S., et al.Niche-based screening in multiple myeloma identifies a kinesin-5 inhibitor with improved selectivity over hematopoietic progenitorsCell Rep.10(5)755-770(2015)
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *